Market Overview

New Study Affirms Masimo Rainbow Pulse CO-Oximetry Accuracy for Noninvasive Carboxyhemoglobin and Methemoglobin Measurements

Masimo (NASDAQ: MASI) announced today a new study in Respiratory Physiology & Neurobiology shows that noninvasive carboxyhemoglobin (SpCO®) and methemoglobin (SpMet®) measurements with Masimo rainbow® Pulse CO-Oximetry™ are accurate and conclude they can be used as an effective first screening test with emergency room patients suspected of suffering carbon monoxide (CO) poisoning.

Posted-In: News FDA

 

Related Articles (MASI)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters